FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response	: 0.5								

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
\cup	obligations may continue. See
	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* AHMED NADIM					2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [CGEM]									(Chec	k all app Direc	ip of Reporting P plicable) ctor er (give title		rson(s) to Is 10% Ov Other (s	vner
(Last)	,	rst) (MOCOLOGY, IN	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/28/2023								Λ	X Office (give title Office (sp below) below) President and CEO					
ONE MAIN STREET, SUITE 1350				4. If Amendment, Date of Original Filed (Month/Day/Year)								r)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CAMBRIDGE MA 02142													X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Si	ate) (Z	Zip)		Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													ended to
		Table	I - No	n-Derivat	tive Se	ecur	rities	Acq	uired,	Dis	posed of	, or I	3enef	ciall	y Owr	ned			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day)				//Year)	Deemed ution Date, / th/Day/Year)					es Acquired (A Of (D) (Instr. 3				cially 1	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) (D)	or Pr	ce	Report Transa						
Common Stock 06/28/2					2023			S		759(1)		\$	11.4	1.4 115,822		,822 D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			tion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		De See (In:	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amour or Number of Shares	er					

Explanation of Responses:

 $1. \ Sale \ of \ shares \ to \ cover \ personal \ income \ tax \ obligations \ upon \ vesting \ of \ restricted \ stock \ units.$

/s/ Jacquelyn Sumer, Attorney-in-Fact

06/29/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.